RxDoctor Payments Data

Sherry Hu

Hematology & Oncology · Issaquah, WANPI 1720279904

Payments from drug & device makers

$21,248in general payments, 2019–2025

Across 19 payments — averaging $1118.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$20K
  • Stemline Therapeutics Inc.$367
  • Athenex Pharmaceutical Division, LLC$350
  • Lilly USA, LLC$164
  • Boston Scientific$142
  • AbbVie$125
  • plus $56 from 4 others

What the payments were for

  • Speaking & faculty fees$35028%
  • Food & beverage$83467%
  • Education$645%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer4$20,045
Stemline Therapeutics Inc.3$367
Athenex Pharmaceutical Division, LLC2$350
Lilly USA, LLC3$164
Boston Scientific2$142
AbbVie1$125
Bristol Myers Squibb1$16
ADC Therapeutics America, Inc.1$16
Gilead1$12
Epizyme, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,248 in reported general payments places this provider in the 55th percentile of 349 hematology & oncology providers in Washington.

See all hematology & oncology providers in Washington

Medicare billing

Part B allowed, 2024
$85,213
Medicare patients
230
Services billed
851

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VerzenioAbemaciclib21$417,429
Lenalidomide21$265,699
XtandiEnzalutamide13$147,994
ZarxioFilgrastim-Sndz18$53,021
EliquisApixaban55$45,842
Abiraterone Acetate80$42,439
XareltoRivaroxaban24$23,723
NivestymFilgrastim-Aafi14$18,445
Gabapentin53$2,255
Morphine Sulfate ErMorphine Sulfate25$2,067
Anastrozole122$1,732
Tamoxifen Citrate46$1,194
Letrozole47$1,175
Hydroxyurea33$756
Doxycycline Hyclate12$683

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCVerzenio$164$417,42921 claims
PfizerEliquis, Nivestym$20,045$64,28769 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 349 hematology & oncology providers in Washington.

Other hematology & oncology in Issaquah

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →